What is the Optimal BCG Dose in Non-Muscle-Invasive Bladder Cancer?

European Urology

Volumn 52, Issue 5, 2007, Pages 1300-1302

  Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPIRUBICIN; INTERLEUKIN 2; ISONIAZID; MITOMYCIN C; TUBERCULOSTATIC AGENT;

BLADDER CANCER; CANCER RISK; CARCINOMA IN SITU; CLINICAL TRIAL; DISEASE FREE INTERVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; EDITORIAL; FEVER; FOLLOW UP; HUMAN; MENTAL IRRITATION; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASM INVASIVENESS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34548836803     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.05.010     Document Type: Editorial

References (11)

1. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
2. Witjes J.A., van der Meijden A.P.M., and Debruyne F.M.J. The use of intravesical BCG in superficial bladder tumors. An overview. Urol Int 45 (1990) 129-136
3. Shintani Y., Sawada Y., Inagaki T., Kohjimoto Y., Uekado Y., and Shinka T. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int J Urol 14 (2007) 140-146
4. Saint F., Kurth N., Maille P., et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107 (2003) 434-440
5. Witjes J.A., van der Meijden A.P.M., Witjes W.P.J., Doesburg W., Schaafsma H.E., and Debruyne F.M.J. A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Intravesical instillations in superficial bladder cancer. Eur J Cancer 29A (1993) 1672-1676
6. Thalmann G.N., Birkhaeuser F., Rentsch C.A., Ochsner K., and Studer U.E. Bacillus Calmette-Guérin (BCG) used for intravesical instillations in the treatment of nonmuscle invasive transitional cell carcinoma (TCC) of the bladder: does the strain matter. Eur Urol Suppl 6 (2007) 61 (abstract no. 153)
7. Luftenegger W., Ackermann D.K., Futterlieb A., et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155 (1996) 483-487
8. Oosterlinck W., van der Meijden A.P.M., Sylvester R., et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. EAU Guidelines (2007) 1-18
9. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., and Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
10. Pagano F., Bassi P., Milani C., Meneghini A., Maruzzi D., and Garbeglio A. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective?. J Urol 146 (1991) 32-35
11. Rivera P., Orio M., Hinostroza J., et al. Our experience with 1 mg BCG vaccine instillation in T1 stage cancer of the bladder. Actas Urol Esp 23 (1999) 757-762